Home > Drugs A-Z > Pediatric Infuvite Multiple Vitamins for Infusion

Pediatric Infuvite Multiple Vitamins for Infusion (Sandoz Canada Inc)

Available Formats

Dosage Form Package Information Links
INJECTION, SOLUTION 10 VIAL in 1 CARTON (54643-5646-1) > 5 mL in 1 VIAL Label Information
INJECTION, SOLUTION 2 VIAL in 1 CARTON (54643-5646-0) > 5 mL in 1 VIAL Label Information

Complete Pediatric Infuvite Multiple Vitamins for Infusion Information

  • SPL UNCLASSIFIED SECTION

    For intravenous infusion after dilution only.


  • DESCRIPTION

    INFUVITE Pediatric is a sterile product consisting of two vials: a 4 mL single-dose vial labeled Vial 1 and a 1 mL single-dose vial labeled Vial 2.

    Each 4 mL of Vial 1 contains:

    Ascorbic acid (Vitamin C) ......................................... 80 mg

    Vitamin A1 (as palmitate)...................................... 2,300 IU

    Vitamin D31 (cholecalciferol) ................................... 400 IU

    Thiamine (Vitamin B1)
    (as the hydrochloride)............................................ 1.2 mg

    Riboflavin (Vitamin B2)
    (as riboflavin 5-phosphate sodium) ....................... 1.4 mg

    Pyridoxine HCl (Vitamin B6) ....................................... 1 mg

    Niacinamide .............................................................. 17 mg

    Dexpanthenol
    (as d-pantothenyl alcohol) ........................................ 5 mg

    Vitamin E1 (dl-α-tocopheryl acetate)........................... 7 IU

    Vitamin K11.............................................................. 0.2 mg

    Inactive ingredients: 50 mg polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment and water for injection.

    1Polysorbate 80 is used to water solubilize the oil-soluble vitamins A, D, E, and K.

    Each 1 mL of Vial 2 contains:

    Folic acid............................................................... 140 mcg

    Biotin....................................................................... 20 mcg

    Vitamin B12 (cyanocobalamin).................................. 1 mcg

    Inactive ingredients: 75 mg mannitol, citric acid and/or sodium citrate for pH adjustment and water for injection.

    Vitamin A 2,300 IU equals 0.7 mg

    Vitamin D 400 IU equals 10 mcg

    Vitamin E 7 IU equals 7 mg

    Multiple vitamin preparation for intravenous infusion: INFUVITE Pediatric (Multiple Vitamins for Infusion) makes available a combination of important oil-soluble and water-soluble vitamins in an aqueous solution, formulated for incorporation into intravenous solutions. The liposoluble vitamins A, D, E, and K have been solubilized in an aqueous medium with polysorbate 80, permitting intravenous administration of these vitamins.

    Contains no more than 30 mcg/L of aluminum (combined vials 1 and 2).


  • INDICATIONS AND USAGE

    INFUVITE Pediatric is indicated as a daily multivitamin maintenance dosage for infants and children up to 11 years of age receiving parenteral nutrition.

    INFUVITE Pediatric is also indicated in other situations where administration by the intravenous route is required. Such situations include surgery, extensive burns, fractures and other trauma, severe infectious diseases, and comatose states, which may provoke a “stress” situation with profound alterations in the body's metabolic demands and consequent tissue depletion of nutrients. The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy.

    INFUVITE Pediatric (administered in intravenous fluids under proper dilution) contributes intake of necessary vitamins toward maintaining the body's normal resistance and repair processes.

    Patients with multiple vitamin deficiencies or with markedly increased requirements may be given multiples of the daily dosage for two or more days, as indicated by the clinical status. Blood vitamin concentrations should be periodically monitored to ensure maintenance of adequate levels, particularly in patients receiving parenteral multivitamins as their sole source of vitamins for long periods of time.


  • CONTRAINDICATIONS

    INFUVITE Pediatric is contraindicated where there is a preexisting hypervitaminosis, or a known hypersensitivity to any of the vitamins or excipients in the product.

    Allergic reactions have been known to occur following intravenous administration of thiamine and vitamin K. The formulation is contraindicated prior to blood sampling for detection of megaloblastic anemia, as the folic acid and the cyanocobalamin in the vitamin solution can mask serum deficits.


  • WARNINGS

    INFUVITE Pediatric is administered in intravenous solutions, which may contain aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solution, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.


  • PRECAUTIONS

    Caution should be exercised when administering INFUVITE Pediatric to patients on warfarin sodium-type anticoagulant therapy. In such patients, vitamin K may antagonize the hypoprothrombinemic response to anticoagulant drugs. In such patients, periodic monitoring of prothrombin time/INR response is essential in determining the appropriate dosage of anticoagulant therapy.

    Adequate blood levels of vitamin E are achieved when INFUVITE Pediatric is given to infants at the recommended dosage. Larger doses or supplementation with oral or parenteral vitamin E are not recommended because elevated blood levels of vitamin E may result.

    Studies have shown that vitamin A may adhere to plastic, resulting in inadequate vitamin A administration in the doses recommended with INFUVITE Pediatric. Additional vitamin A supplementation may be required, especially in low-birth-weight infants. Long-standing specific vitamin deficiencies may require additional therapeutic amounts of specific vitamins to supplement the maintenance vitamins provided by INFUVITE Pediatric.

    In patients receiving parenteral multivitamins, blood vitamin concentrations should be periodically monitored to determine if vitamin deficiencies or excesses are developing.

    Polysorbates have been associated with the E-Ferol syndrome (thrombocytopenia, renal dysfunction, hepatomagaly, cholestasis, ascites, hypotension and metabolic acidosis) in low-birth-weight infants. However, no such adverse reports have been associated with the use of pediatric multiple vitamins for infusion such as INFUVITE Pediatric.

    INFUVITE Pediatric should be aseptically transferred to the infusion fluid.

    Drug-Drug Interactions

    Physical incompatibilities

    INFUVITE Pediatric (Multiple Vitamins for Infusion) is not physically compatible with alkaline solutions or moderately alkaline drugs such as acetazolamide, and chlorothiazide sodium, aminopylline or sodium bicarbonate. INFUVITE Pediatric is not physically compatible with ampicillin and it may not be physically compatible with tetracycline HCl. It has also been reported that folic acid is unstable in the presence of calcium salts such as calcium gluconate. Direct addition to intravenous fat emulsions is not recommended. Consult appropriate references for listings of physical compatibility of solutions and drugs with the vitamin infusion. In such circumstances, admixture or Y-site administration with vitamin solutions should be avoided.

    Some of the vitamins in INFUVITE Pediatric may react with vitamin K bisulfite or sodium bisulfite; if bisulfite solutions are necessary, patients should be monitored for Vitamin A, thiamine, and ascorbic acid deficiencies.

    Clinical Interactions

    A number of interactions between vitamins and drugs have been reported which may affect the metabolism of either agent. The following are examples of these types of interactions.

    Folic acid may lower the serum concentration of phenytoin resulting in increased seizure frequency.Conversely, phenytoin may decrease serum folic acid concentrations and, therefore, should be avoided in pregnancy. Folic acid may decrease the patient's response to methotrexate therapy.

    Pyridoxine may decrease the efficacy of levodopa by increasing its metabolism. Concomitant administration of hydralazine or isoniazid may increase pyridoxine requirements.

    In patients with pernicious anemia, the hematological response to vitamin B12 therapy may be inhibited by concomitant administration of chloramphenicol.

    Several vitamins have been reported to decrease the activity of certain antibiotics. Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid have been reported to decrease the antibiotic activity of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin. Bleomycin is inactivated in vitro by ascorbic acid and riboflavin.

    Vitamin K may antagonize the hypoprothrombinemic effect of oral anticoagulants (see PRECAUTIONS).

    Consult appropriate references for additional specific vitamin-drug interactions.

    Drug-Laboratory Test Interactions

    Ascorbic acid in the urine may cause false negative urine glucose determinations.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenicity, mutagenicity, and fertility studies have not been performed.


  • ADVERSE REACTIONS

    There have been rare reports of anaphylactic reactions following parenteral multivitamin administration. Rare reports of anaphylactoid reactions have also been reported after large intravenous doses of thiamine. The risk, however, is negligible if thiamine is coadministered with other vitamins of the B group. There have been no reports of fatal anaphylactoid reactions associated with multivitamin preparations for infusion.

    There have been rare reports of the following types of reactions:

    Dermatologic – rash, erythema, pruritis

    CNS – headache, dizziness, agitation, anxiety

    Ophthalmic – diplopia

    Allergic – urticaria, shortness of breath, wheezing and angioedema.


  • OVERDOSAGE

    The possibility of hypervitaminosis A or D should be borne in mind. Clinical manifestations of hypervitaminosis A have been reported in patients with renal failure receiving 1.5 mg/day retinol. Therefore, vitamin A supplementation of renal failure patients should be undertaken with caution.


  • DOSAGE AND ADMINISTRATION

    INFUVITE Pediatric is ready for immediate use in infants and children up to 11 years of age when added to intravenous infusion fluids.

    INFUVITE Pediatric should not be given as a direct, undiluted intravenous injection as it may give rise to dizziness, faintness and possible tissue irritation.

    A daily dose of INFUVITE Pediatric (4 mL of Vial 1 plus 1 mL of Vial 2) should be added directly to not less than 100 mL of intravenous dextrose, saline or similar infusion solutions.

    For administration to infants weighing < 1 kg:

    The daily dose is 30% of the contents of Vial 1 (1.2 mL) and of Vial 2 (0.3 mL). Do not exceed this daily dose. Supplemental vitamin A may be required for low-birth-weight infants.

    For administration to infants weighing ≥1 kg and < 3 kg: The daily dose is 65% of the contents of Vial 1 (2.6 mL) and of Vial 2 (0.65 mL). Do not exceed this daily dose. Supplemental vitamin A may be required for low-birth-weight infants.

    For administration to infants and children weighing ≥3 kg up to 11 years of age: The daily dose is the entire contents of Vial 1 (4 mL) and of Vial 2 (1 mL), unless there is clinical or laboratory evidence for increasing or decreasing the dosage.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

    After INFUVITE Pediatric is diluted in an intravenous infusion, the resulting solution is ready for immediate use. Some of the vitamins in this product, particularly A, D, and riboflavin, are light sensitive, therefore, exposure to light should be minimized. DISCARD ANY UNUSED PORTION


  • HOW SUPPLIED

    INFUVITE Pediatric – NDC 54643-5646-0, is available in boxes containing 2 vials – Vial 1 (4 mL) and Vial 2 (1 mL), both vials to be used for a single dose.

    INFUVITE Pediatric – NDC 54643-5646-1, is available in boxes containing 10 vials – 5 each of Vial 1 (4 mL) and 5 each of Vial 2 (1 mL), one Vial 1 plus one Vial 2 to be used for a single dose.

    Store under refrigeration 2-8°C (36-46°F).

    Rx only

    Manufactured by
    Sandoz Canada Inc.
    145 Jules-Leger Street Boucherville, QC, Canada J4B 7K8

    Distributed by
    Baxter Healthcare Corporation
    Clintec Nutrition Division Deerfield, IL 60015 USA

    Printed in Canada

    D1006224 Rev. September 2007

    ® INFUVITE is a registered trademark of Sandoz Canada Inc.


  • Infuvite Pediatric Carton

    2A9008 NDC 54643-5646-1

    Baxter

    INFUVITE PEDiatric Multiple Vitamins for Infusion

    For intravenous infusion after dilution only.

    Sterile Rx only

    Contains 5 each of Vial 1 (4 mL) and Vial 2 (1 mL).

    One vial of each to be used for a single dose.

    Store under refrigeration, 2-8°C (36-46°F).

    Infuvite Pediatric Carton

  • INGREDIENTS AND APPEARANCE
    PEDIATRIC INFUVITE MULTIPLE VITAMINS FOR INFUSION 
    asorbic acid, vitamin a palmitate, cholecalciferol, thiamine hydrochloride, riboflavin 5-phosphate sodium, pyridoxine hydrochloride, niacinamide, dexpanthenol, alpha-tocopherol acetate, vitamin k1, folic acid, biotin, cyanocobalamin injection, solution
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:54643-5646
    Route of Administration INTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    ASCORBIC ACID (UNII: PQ6CK8PD0R) (ASCORBIC ACID - UNII:PQ6CK8PD0R) ASCORBIC ACID 80 mg  in 5 mL
    VITAMIN A PALMITATE (UNII: 1D1K0N0VVC) (VITAMIN A - UNII:81G40H8B0T) VITAMIN A 2300 [iU]  in 5 mL
    CHOLECALCIFEROL (UNII: 1C6V77QF41) (CHOLECALCIFEROL - UNII:1C6V77QF41) CHOLECALCIFEROL 400 [iU]  in 5 mL
    THIAMINE HYDROCHLORIDE (UNII: M572600E5P) (THIAMINE - UNII:X66NSO3N35) THIAMINE 1.2 mg  in 5 mL
    RIBOFLAVIN 5'-PHOSPHATE SODIUM (UNII: 20RD1DZH99) (RIBOFLAVIN - UNII:TLM2976OFR) RIBOFLAVIN 1.4 mg  in 5 mL
    PYRIDOXINE HYDROCHLORIDE (UNII: 68Y4CF58BV) (PYRIDOXINE - UNII:KV2JZ1BI6Z) PYRIDOXINE HYDROCHLORIDE 1 mg  in 5 mL
    NIACINAMIDE (UNII: 25X51I8RD4) (NIACINAMIDE - UNII:25X51I8RD4) NIACINAMIDE 17 mg  in 5 mL
    DEXPANTHENOL (UNII: 1O6C93RI7Z) (DEXPANTHENOL - UNII:1O6C93RI7Z) DEXPANTHENOL 5 mg  in 5 mL
    ALPHA-TOCOPHEROL ACETATE (UNII: 9E8X80D2L0) (ALPHA-TOCOPHEROL - UNII:H4N855PNZ1) ALPHA-TOCOPHEROL ACETATE 7 [iU]  in 5 mL
    PHYTONADIONE (UNII: A034SE7857) (PHYTONADIONE - UNII:A034SE7857) PHYTONADIONE 0.2 mg  in 5 mL
    FOLIC ACID (UNII: 935E97BOY8) (FOLIC ACID - UNII:935E97BOY8) FOLIC ACID 140 ug  in 5 mL
    BIOTIN (UNII: 6SO6U10H04) (BIOTIN - UNII:6SO6U10H04) BIOTIN 20 ug  in 5 mL
    CYANOCOBALAMIN (UNII: P6YC3EG204) (CYANOCOBALAMIN - UNII:P6YC3EG204) CYANOCOBALAMIN 1 ug  in 5 mL
    Inactive Ingredients
    Ingredient Name Strength
    POLYSORBATE 80 (UNII: 6OZP39ZG8H)  
    ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)  
    SODIUM CITRATE (UNII: 1Q73Q2JULR)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    MANNITOL (UNII: 3OWL53L36A)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:54643-5646-0 2 in 1 CARTON
    1 5 mL in 1 VIAL
    2 NDC:54643-5646-1 10 in 1 CARTON
    2 5 mL in 1 VIAL
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA021265 02/21/2001
    Labeler - Sandoz Canada Inc (244062071)